EGFR and ganglioneuroma: The proliferation marker Ki-67 was significantly decreased in groups treated with anti-EGFR (17.1±1.37%), anti-EGFR-GN (9.06±0.60%), and anti-EGFR-GN+NIR-PTT (6.19±2.5%) relative to control (P<0.001).